Engineered Herpes Virus Yields Strong Responses in Advanced Melanoma as Phase 3 Trial Begins

Oncolytic HSV-1 with nivolumab triggered tumor shrinkage or disappearance throughout the body in patients who had not responded to existing immunotherapies.